Details for Patent: 7,223,440
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Which drugs does patent 7,223,440 protect, and when does it expire?
Patent 7,223,440 protects BYDUREON, BYDUREON PEN, and BYDUREON BCISE, and is included in two NDAs.
Protection for BYDUREON has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has twenty-one patent family members in fourteen countries.
Summary for Patent: 7,223,440
Title: | Residual solvent extraction method and microparticles produced thereby |
Abstract: | Methods for preparing microparticles having reduced residual solvent levels. Microparticles are contacted with a non-aqueous washing system to reduce the level of residual solvent in the microparticles. Preferred non-aqueous washing systems include 100% ethanol and a blend of ethanol and heptane. A solvent blend of a hardening solvent and a washing solvent can be used to harden and wash microparticles in a single step, thereby eliminating the need for a post-hardening wash step. |
Inventor(s): | Rickey; Michael E. (Loveland, OH), Ramstack; J. Michael (Lunenburg, MA), Kumar; Rajesh (Marlborough, MA) |
Assignee: | Alkermes, Inc. (Cambridge, MA) |
Application Number: | 11/312,371 |
Patent Claim Types: see list of patent claims | Formulation; Process; Use; |
Drugs Protected by US Patent 7,223,440
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Astrazeneca Ab | BYDUREON | exenatide synthetic | FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS | 022200-001 | Jan 27, 2012 | DISCN | Yes | No | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | |||||
Astrazeneca Ab | BYDUREON PEN | exenatide synthetic | FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS | 022200-002 | Feb 28, 2014 | DISCN | Yes | No | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | |||||
Astrazeneca Ab | BYDUREON BCISE | exenatide synthetic | SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS | 209210-001 | Oct 20, 2017 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 7,223,440
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Austria | 501711 | See Plans and Pricing | |||
Canada | 2454027 | See Plans and Pricing | |||
Cyprus | 1112348 | See Plans and Pricing | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |